Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer

Article ID	Journal	Published Year	Pages	File Type
5987502	The Journal of Thoracic and Cardiovascular Surgery	2016	9 Pages	PDF

Abstract

Metformin exposure in diabetic patients with early-stage non-small cell lung cancer may be associated with improved progression-free survival, but no effect was seen on overall survival. Further studies are warranted to evaluate if there is a therapeutic role for metformin in the treatment of non-small cell lung cancer.

Keywords

AMPK IGF-1 ECoG AMP-activated protein kinase PFs Survival progression-free survival overall survival Diabetes Lung cancer Non–small cell lung cancer NSCLC body mass index BMI eastern cooperative oncology group Outcomes insulin-like growth factor 1 Metformin hazard ratio

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Preview

Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer

Authors

Robert A. BS, James MS, Simon DO, John C. MD, Ravi MD, Fatima MD, Gary W. MD, William H. MD, Sanjib PhD, Jeffrey A. PhD, Michael J. MD, Christopher W. MD,